Maxim analyst Jason McCarthy initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $4 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KAPA:
Education
About Us
Working with TipRanks
Follow Us
